Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | AKR1B10 | O60218 | 4/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2271261 | 1.00 | RAB9A (0.48) | RAB9AP4HTMEGFRNPSR1AKR1B10 | |
| SCHEMBL1253149 | 0.83 | RAB9A (0.44) | RAB9AP4HTMNPSR1AKR1B10AKR1B1 | |
| SCHEMBL1253151 | 0.83 | RAB9A (0.44) | RAB9AP4HTMNPSR1AKR1B10AKR1B1 | |
| Hydrochloric Acid SCHEMBL1093091 | 0.82 | RAB9A (0.43) | RAB9AP4HTMNPSR1AKR1B10AKR1B1 | |
| Hydrochloric Acid SCHEMBL1093094 | 0.82 | RAB9A (0.43) | RAB9AP4HTMNPSR1AKR1B10AKR1B1 | |
| Hydrochloric Acid SCHEMBL5275045 | 0.80 | RAB9A (0.45) | RAB9AP4HTMNPSR1AKR1B10AKR1B1 | |
| SCHEMBL2276271 | 0.79 | P4HTM (0.50) | RAB9AP4HTMNPSR1AKR1B10AKR1B1 | |
| SCHEMBL2276273 | 0.79 | P4HTM (0.50) | RAB9AP4HTMNPSR1AKR1B10AKR1B1 | |
| Hydrochloric Acid SCHEMBL1254296 | 0.78 | ACHE (0.42) | RAB9AP4HTMNPSR1AKR1B10AKR1B1 | |
| Hydrochloric Acid SCHEMBL1254295 | 0.78 | ACHE (0.42) | RAB9AP4HTMNPSR1AKR1B10AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173646-B2 | FAB I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2012-05-08 | — | — | US | disclosed |
| US-20110190283-A1 | Fab I Inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2011-08-04 | — | — | US | disclosed |
| US-7790716-B2 | fatty acid biosynthesis inhibitors such as E)-3-(6-aminopyridin-3-yl)-N-methyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)acrylamide, used fro the treatment of bacterial infections; antibiotics | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2010-09-07 | — | — | US | disclosed |
| US-20090275572-A1 | FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7557125-B2 | Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2009-07-07 | — | — | US | disclosed |
| US-7524843-B2 | N-methyl-N-(1-methyl-1H-indol-3-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide as an enzyme inhibitor for both Fab I and Fab K which are used in the biosynthesis of fatty acids; enoyl-acyl-carrier protein renamed Fab 1; bactericides; fungicides; Staphylococcus aureus; antibiotics | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2009-04-28 | — | — | US | disclosed |
| US-20080125423-A1 | Fab I Inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2008-05-29 | — | — | US | disclosed |
| US-7048926-B2 | Methods of agonizing and antagonizing FabK | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2006-05-23 | — | — | US | disclosed |
| EP-1330515-A4 | METHODS OF AGONIZING AND ANTAGONIZING FABK | AFFINIUM PHARM INC (CA) | 2005-12-07 | — | — | EP | disclosed |
| US-20050250810-A1 | FAB I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2005-11-10 | — | — | US | disclosed |
| US-6846819-B1 | Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2005-01-25 | — | — | US | disclosed |
| EP-1226138-B1 | FAB I INHIBITORS | AFFINIUM PHARM INC (CA) | 2004-12-29 | — | — | EP | disclosed |
| US-20040053814-A1 | Methods of agonizing and antagonizing FabK | DEBIOPHARM INTERNATIONAL SA (CH) | 2004-03-18 | — | — | US | disclosed |
| EP-1330515-A1 | METHODS OF AGONIZING AND ANTAGONIZING FABK | SmithKline Beecham Corporation (US) | 2003-07-30 | — | — | EP | disclosed |
| EP-1226138-A4 | FAB I INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-03-05 | — | — | EP | disclosed |
| EP-1226138-A1 | FAB I INHIBITORS | SmithKline Beecham Corporation (US) | 2002-07-31 | — | — | EP | disclosed |
| WO-2002031128-A1 | METHODS OF AGONIZING AND ANTAGONIZING FABK | SMITHKLINE BEECHAM CORPORATION (US) | 2002-04-18 | — | — | WO | disclosed |
| WO-2001027103-A1 | FAB I INHIBITORS | SMITHKLINE BEECHAM CORPORATION (GB) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053814-A1 | Methods of agonizing and antagonizing FabK | ANTXR2, FPR3, BDKRB2 | RAB9A 4140/4885P4HTM 2599/4885EGFR 896/4885 |
| US-20050250810-A1 | FAB I inhibitors | SERPINB1, TFPI, TFPI2 | RAB9A 3129/4885P4HTM 2790/4885EGFR 1653/4885 |
| US-20090275572-A1 | FAB I INHIBITORS | SERPINB1, TFPI, TFPI2 | RAB9A 3129/4885P4HTM 2790/4885EGFR 1653/4885 |
| US-20080125423-A1 | Fab I Inhibitors | SERPINB1, TFPI, TFPI2 | RAB9A 3129/4885P4HTM 2790/4885EGFR 1653/4885 |
| US-20110190283-A1 | Fab I Inhibitors | SERPINB1, TFPI, TFPI2 | RAB9A 3129/4885P4HTM 2790/4885EGFR 1653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.